NGM Biopharmaceuticals, Inc. Common Stock
NGM
NGM was delisted on the 4th of April, 2024.
81 hedge funds and large institutions have $543M invested in NGM Biopharmaceuticals, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 27 increasing their positions, 30 reducing their positions, and 11 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
4% less funds holding
Funds holding: 84 → 81 (-3)
10% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 30
19% less capital invested
Capital invested by funds: $667M → $543M (-$124M)
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PS
Peter Svennilson
|
+$5.67M |
| 2 |
BlackRock
New York
|
+$2.9M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.61M |
| 4 |
Millennium Management
New York
|
+$1.42M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$1.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$1.6M |
| 2 |
Renaissance Technologies
New York
|
-$1.58M |
| 3 |
ACM
Aquilo Capital Management
San Francisco,
California
|
-$1.4M |
| 4 |
SG Americas Securities
New York
|
-$1.29M |
| 5 |
CRC
Curi RMB Capital
Chicago,
Illinois
|
-$1.1M |
NGM Hedge Fund Activity: Q3 2020 in Review
81 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) for Q3 2020, worth a combined $543M — down 19% from $667M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of NGM and 8 opened new positions — a net loss of 3 holders — while 30 trimmed existing stakes and 27 added.
The largest buyer was Peter Svennilson, adding an estimated $5.67M. The largest seller was Arrowstreet Capital, exiting entirely with an estimated $1.6M sold.
- 81 institutional investors held NGM Biopharmaceuticals, Inc. Common Stock (NGM) as of Q3 2020, down from 84 in Q2 2020.
- Funds reported $543M of NGM Biopharmaceuticals, Inc. Common Stock stock for Q3 2020, down 19% quarter-over-quarter.
- 8 funds opened new NGM Biopharmaceuticals, Inc. Common Stock positions in Q3 2020 and 11 closed out, a net change of -3 holders.
- The largest NGM Biopharmaceuticals, Inc. Common Stock buyer in Q3 2020 was Peter Svennilson, an estimated $5.67M added.
- The largest NGM Biopharmaceuticals, Inc. Common Stock seller in Q3 2020 was Arrowstreet Capital, an estimated $1.6M sold.
Based on aggregated 13F filings for Q3 2020.